CPHIHIGH SIGNALFINANCIAL10-K

CPHI achieved a dramatic turnaround with stockholders' equity surging 194% to $22.7M and operating cash flow turning positive, indicating either significant capital injection or fundamental business improvement.

The massive increase in stockholders' equity combined with a 24% increase in outstanding shares suggests a substantial equity raise that has strengthened the balance sheet. The company's transition from negative $466K to positive $148K operating cash flow, along with significant improvement in gross profit losses, indicates meaningful operational progress despite continued net losses.

Comparing 2026-04-01 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

CPHI underwent a dramatic financial transformation, with stockholders' equity nearly tripling and total assets doubling, largely driven by what appears to be a significant equity financing given the 24% increase in share count. While the company remains unprofitable, operating metrics improved substantially with operating cash flow turning positive and gross losses narrowing by 93%. The overall picture suggests CPHI has secured necessary capital to fund operations while making meaningful progress toward profitability, though cash reserves declined and working capital management remains a focus area.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+193.5%
$7.7M$22.7M

Equity base grew 193.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Operating Cash Flow
Cash Flow
+131.8%
-$466K$148K

Operating cash flow surged 131.8% — exceptional cash generation, highest quality earnings signal.

Total Assets
Balance Sheet
+108.2%
$14.9M$31.0M

Asset base grew 108.2% — expansion through organic growth, acquisitions, or capital deployment.

Gross Profit
P&L
+93.4%
-$2.0M-$132K

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Capital Expenditure
Cash Flow
+54.4%
$38K$59K

Capital expenditure jumped 54.4% — major investment cycle underway; assess returns on deployment.

Current Liabilities
Balance Sheet
+47.5%
$5.0M$7.4M

Current liabilities surged 47.5% — significant near-term obligations; verify ability to meet short-term debt.

Cash & Equivalents
Balance Sheet
-42.5%
$600K$345K

Cash declined 42.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Net Income
P&L
+32.7%
-$4.7M-$3.2M

Net income grew 32.7% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+29.4%
-$4.6M-$3.2M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Inventory
Balance Sheet
-28.5%
$2.3M$1.6M

Inventory reduced 28.5% — lean inventory management or demand outpacing supply.

LANGUAGE CHANGES
NEW — 2026-04-01
PRIOR — 2025-03-31
ADDED
The number of outstanding shares of the registrant s common stock on March 25, 2026, was 40,522,002 .
69 SIGNATURES 70 EXHIBIT INDEX 71 FINANCIAL STATEMENTS F-1 i FORWARD-LOOKING STATEMENTS The statements contained in this report with respect to our financial condition, results of operations and business that are not historical facts are forward-looking statements .
2 Industry Background and Market Opportunities China s pharmaceutical industry is highly policy-driven, with policies such as generic drug consistency evaluation and centralized volume-based procurement (CP) exerting a significant impact on the market landscape.
According to the National Bureau of Statistics of China, in the first half of 2024, pharmaceutical enterprises above a designated size achieved operating income of RMB 1.47 trillion (approximately USD 205 billion), a year-on-year decrease of 1.4%, and profits of RMB 211.2 billion (approximately USD 29.5 billion), down 1.2% year on year.
Unlike Western markets, China s pharmaceutical sector features a large number of small and medium-sized manufacturers, low industrial concentration, and fierce competition over homogeneous products.
+7 more — sign up free →
REMOVED
The number of outstanding shares of the registrant s common stock on March 24, 2025, was 32,619,109 .
73 SIGNATURES 74 EXHIBIT INDEX 75 FINANCIAL STATEMENTS F-1 i FORWARD-LOOKING STATEMENTS The statements contained in this report with respect to our financial condition, results of operations and business that are not historical facts are forward-looking statements .
2 Industry Background and Market Opportunities China s pharmaceutical industry is heavily policy-driven.
Policies like the generic drug consistency evaluation and centralized volume-based procurement (CP) significantly shape the market.
According to the National Bureau of Statistics of China, in the first half of 2024, pharmaceutical enterprises above a designated size reported operating income of RMB 1.47 trillion (approximately $205 billion), a 1.4% year-on-year decline, and profits of RMB 211.2 billion (approximately $29.5 billion), down 1.2%.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →